Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056314 | 1.00 | CHRM2 (0.44) | CHRM2CHRM4CHRM5ACHEELANE | |
| SCHEMBL3056318 | 1.00 | CHRM2 (0.44) | CHRM2CHRM4CHRM5ACHEELANE | |
| SCHEMBL15700421 | 1.00 | CHRM2 (0.44) | CHRM2CHRM4CHRM5ACHEELANE | |
| SCHEMBL3056320 | 1.00 | CHRM2 (0.44) | CHRM2CHRM4CHRM5ACHEELANE | |
| SCHEMBL14146467 | 0.89 | KMT2A (0.45) | CHRM2CHRM4CHRM5ELANEF2 | |
| SCHEMBL25368856 | 0.86 | ACE (0.42) | MAPTHPGDALDH1A1 | |
| SCHEMBL891774 | 0.82 | MAPT (0.47) | ACHEELANEF2PLGCTSG | |
| SCHEMBL3061199 | 0.82 | KMT2A (0.48) | CHRM2CHRM4CHRM5ACHEELANE | |
| SCHEMBL24699789 | 0.82 | KMT2A (0.48) | CHRM2CHRM4CHRM5ACHEELANE | |
| SCHEMBL8936087 | 0.82 | MAPT (0.47) | ACHEELANEF2PLGCTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055363-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4724438-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| EP-4171567-B1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4171568-B1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12384789-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250188056-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| CN-115835866-B | Cereblon binding compounds, compositions thereof, and methods for their use in therapy | 新基公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025090514-A1 | COVALENT SARM1 INHIBITORS | NURA BIO, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7732609-B2 | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732609-B2 | 5-(arylsulfonyl)-pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | ELAN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| EP-1549278-A4 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1549278-A2 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004012684-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | CHRM2 1634/4885CHRM4 2004/4885CHRM5 2157/4885 |
| US-20070155753-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | CHRM2 11/4885CHRM4 106/4885CHRM5 10/4885 |
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | CHRM2 2/4885CHRM4 6/4885CHRM5 3/4885 |
| US-12421213-B2 | Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | CHRM2 4796/4885CHRM4 4848/4885CHRM5 4827/4885 |
| US-20100267747-A1 | 5-(Arylsulfonyl)-Pyrazolopiperidines | PSEN1, PSEN2, C1S | CHRM2 11/4885CHRM4 106/4885CHRM5 10/4885 |
| US-20250188056-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, ESRRA | CHRM2 150/4885CHRM4 257/4885CHRM5 239/4885 |
| US-12384789-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | CHRM2 3171/4885CHRM4 3665/4885CHRM5 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.